Trends of Second‐Line Eradication Therapy for<i>Helicobacter pylori</i>in Japan: A Multicenter Study in the Tokyo Metropolitan Area

Abstract

From 2007 to 2011, there were no significant trends in the second-line eradication rates and the rates remained consistently high. From the viewpoint of high prevalence of CAM resistance in Japan, triple therapy with PPI, AMPC and MNZ may be a better strategy for first-line therapy compared to triple therapy with PPI, AMPC and CAM.